Yahong Pharmaceutical announced that the company signed a conditional “Exclusive License Agreement” with Theramex HQUK Limited. Theramex will obtain exclusive rights from APL-1702 in European countries, Australia, New Zealand, and Turkey, and the company retains relevant rights in the rest of the world. The total amount of this transaction exceeded US$250 million, including a down payment of US$15 million, recent registration milestone payments of US$11 million, commercial milestone payments, and tiered sales commissions. The down payment must meet conditions such as signing a supply agreement and passing an audit of the production site. This transaction does not constitute a related transaction or major asset restructuring. It has been reviewed and approved by the company's board of directors, and there is no need to submit it to the shareholders' meeting for review. There is uncertainty about whether the product can be approved for sale in authorized regions.

Yahong Pharmaceutical announced that the company signed a conditional “Exclusive License Agreement” with Theramex HQUK Limited. Theramex will obtain exclusive rights from APL-1702 in European countries, Australia, New Zealand, and Turkey, and the company retains relevant rights in the rest of the world. The total amount of this transaction exceeded US$250 million, including a down payment of US$15 million, recent registration milestone payments of US$11 million, commercial milestone payments, and tiered sales commissions. The down payment must meet conditions such as signing a supply agreement and passing an audit of the production site. This transaction does not constitute a related transaction or major asset restructuring. It has been reviewed and approved by the company's board of directors, and there is no need to submit it to the shareholders' meeting for review. There is uncertainty about whether the product can be approved for sale in authorized regions.